Fluconazole Ilan Pharm, 150 mg capsules, No. 1

In stock: 10
$42.00

Ingredients

Active ingredient: fluconazole;

1 capsule contains 150 mg of fluconazole; excipients: lactose monohydrate; potato starch; magnesium stearate; anhydrous colloidal silicon dioxide; capsule shell composition: gelatin, titanium dioxide (E 171), indigo carmine blue (E 132).

Description

Hard gelatin capsules No. 1, cylindrical in shape with hemispherical edges; the body is white, and the cap is light blue or blue; Capsule contents: a white or nearly white, odorless powder.

Pharmacological Properties

Antifungal agents for systemic use. Triazole derivatives. ATC code J02A C01.

Mechanism of action.

Fluconazole, an antifungal agent of the triazole class, is a potent and selective inhibitor of fungal enzymes necessary for ergosterol synthesis. Its primary mechanism of action is the inhibition of the cytochrome P450-mediated 14-alpha-lanosterol demethylation in fungi, which is an essential step in the biosynthesis of fungal ergosterol. The accumulation of 14-alpha-methylsterols correlates with the subsequent loss of ergosterol through the fungal cell membrane and may account for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems. Administration of fluconazole at a dose of 50 mg daily for 28 days does not affect plasma testosterone levels in men or endogenous steroid levels in women of reproductive age. Fluconazole at a dose of 200–400 mg per day has no clinically significant effect on endogenous steroid levels or on the response to adrenocorticotropic hormone (ACTH) in healthy male volunteers. A drug interaction study with antipyrine demonstrated that a single or repeated dose of 50 mg of fluconazole does not affect the metabolism of antipyrine.

In vitro susceptibility

In vitro, fluconazole exhibits antifungal activity against the most common Candida species (including C. albicans, C. parapsilosis, and C. tropicalis).C. glabrata exhibits a wide range of susceptibility to fluconazole, whereas C. krusei is resistant to it. Fluconazole also demonstrates in vitro activity against Cryptococcus neoformans and Cryptococcus gattii, as well as against the endemic molds Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and Paracoccidioides brasiliensis.

Mechanism of resistance.

Microorganisms of the genus Candida exhibit numerous mechanisms of resistance to azole antifungals. Fluconazole exhibits a high minimum inhibitory concentration against fungal strains that possess one or more resistance mechanisms, which negatively affects its efficacy in vivo and in clinical practice. Cases of Candida spp. superinfection caused by species other than C. albicans, which are often resistant to fluconazole (e.g., Candida krusei), have been reported. Alternative antifungal agents should be used to treat such cases.

Pharmacokinetics

The pharmacokinetic properties of fluconazole are similar following intravenous and oral administration.

Absorption.

Fluconazole is well absorbed following oral administration, and plasma concentrations and systemic bioavailability exceed 90% of the plasma fluconazole levels achieved with intravenous administration. Concomitant food intake does not affect the absorption of the drug when administered orally. Peak plasma concentration is reached 0.5–1.5 hours after administration. Plasma concentrations of the drug are proportional to the dose. Steady-state concentrations of 90% are reached on the second day of treatment when a loading dose twice the usual daily dose is administered on the first day.

Distribution.

The volume of distribution is approximately equal to the total body fluid volume. Plasma protein binding is low (11–12%). Fluconazole penetrates well into all body fluids studied. Fluconazole levels in saliva and sputum are similar to plasma concentrations. In patients with fungal meningitis, fluconazole levels in cerebrospinal fluid reach 80% of plasma concentrations. High concentrations of fluconazole in the skin, exceeding serum levels, are achieved in the stratum corneum, epidermis, dermis, and sweat. Fluconazole accumulates in the stratum corneum. When administered at a dose of 50 mg once daily, the concentration of fluconazole after 12 days of treatment was 73 μg/g, and 7 days after the end of treatment, the concentration was still 5.8 μg/g. When administered at a dose of 150 mg once weekly, the concentration of fluconazole on the 7th day of treatment was 23.4 μg/g; 7 days after the next dose was administered, the concentration was still 7.1 μg/g. The concentration of fluconazole in the nails after 4 months of treatment with 150 mg once weekly was 4.05 μg/g in healthy volunteers and 1.8 μg/g in patients with nail disorders; fluconazole was detected in nail samples 6 months after completion of therapy.

Biotransformation.

Fluconazole is metabolized to a minor extent. Following administration of a dose labeled with radioactive isotopes, only 11% of fluconazole is excreted in the urine in a metabolized form. Fluconazole is a selective inhibitor of the CYP2C9 and CYP3A4 isoenzymes, as well as an inhibitor of the CYP2C19 isoenzyme. Elimination. The half-life of fluconazole in plasma is approximately 30 hours. Most of the drug is excreted by the kidneys, with 80% of the administered dose appearing in the urine unchanged. The clearance of fluconazole is proportional to creatinine clearance. No circulating metabolites have been detected. The drug’s long half-life in plasma allows for a single-dose regimen in the treatment of vaginal candidiasis, as well as once-weekly dosing for other indications.

Renal impairment.

In patients with severe renal insufficiency (glomerular filtration rate less than 20 mL/min), the half-life increases from 30 to 98 hours. Therefore, the dose of fluconazole must be reduced in this patient population. Fluconazole is removed by hemodialysis and, to a lesser extent, by intraperitoneal dialysis. A 3-hour hemodialysis session reduces the plasma concentration of fluconazole by approximately 50%.

Elderly Patients

Changes in pharmacokinetics in elderly patients depend on renal function.

Indications for Use

Acute vaginal candidiasis when local therapy is not appropriate.

Candidal balanitis, when local therapy is not appropriate.

Contraindications

  • Hypersensitivity to fluconazole, other azole compounds, or any of the drug’s excipients.
  • Concomitant use of fluconazole and terfenadine in patients receiving repeated doses of fluconazole at 400 mg/day or higher (based on the results of a drug interaction study involving repeated dosing).
  • Concomitant use of fluconazole with other drugs that prolong the QT interval and are metabolized by the CYP2A4 enzyme (e.g., cisapride, astemizole, pimozide, quinidine, and erythromycin).

Interactions with Other Medications and Other Types of Interactions

The concomitant use of fluconazole and the drugs listed below is contraindicated.

Cisapride. Adverse cardiac reactions, including “pirouette”-type paroxysmal ventricular tachycardia, have been reported in patients receiving concomitant fluconazole and cisapride. A controlled study demonstrated that the concomitant use of 200 mg of fluconazole once daily and 20 mg of cisapride four times daily resulted in a significant increase in cisapride plasma levels and QT interval prolongation. Concomitant use of fluconazole and cisapride is contraindicated (see the “Contraindications” section).

Terfenadine. Due to cases of severe cardiac arrhythmias caused by QTc prolongation in patients who took azole antifungal medications concomitantly with terfenadine, studies on the interaction between these drugs were conducted. In one study, no prolongation of the QTc interval was observed with fluconazole at a dose of 200 mg daily. Another study involving fluconazole at doses of 400 mg and 800 mg per day demonstrated that the use of fluconazole at doses of 400 mg per day or higher significantly increases the plasma concentration of terfenadine when these drugs are used concomitantly. Concomitant use of fluconazole at doses of 400 mg or higher with terfenadine is contraindicated (see the “Contraindications” section). When fluconazole is administered at doses below 400 mg per day concomitantly with terfenadine, the patient’s condition should be closely monitored.

Astemizole. Concomitant use of fluconazole and astemizole may reduce the clearance of astemizole. The resulting increase in astemizole plasma concentrations may lead to QT interval prolongation and, in rare cases, to “pirouette”-type paroxysmal ventricular tachycardia. Concomitant use of fluconazole and astemizole is contraindicated.

Pimozide and quinidine. Concomitant use of fluconazole and pimozide or quinidine may lead to inhibition of the metabolism of pimozide or quinidine, although no relevant in vitro or in vivo studies have been conducted. Increased plasma concentrations of pimozide or quinidine may cause QT interval prolongation and, in rare cases, lead to the development of paroxysmal “pirouette” ventricular tachycardia. Concomitant use of fluconazole and pimozide or quinidine is contraindicated.

Erythromycin. Concomitant use of erythromycin and fluconazole may increase the risk of cardiotoxicity (QT interval prolongation, paroxysmal ventricular tachycardia of the “pirouette” type) and, as a result, sudden cardiac death. The use of this drug combination is contraindicated.

Amiodarone. Concomitant use of fluconazole with amiodarone may lead to inhibition of amiodarone metabolism. An association has been observed between amiodarone use and QT interval prolongation. Concomitant use of fluconazole and amiodarone is contraindicated (see the “Contraindications” section). Concomitant use of fluconazole and the drugs listed below is not recommended.

Halofantrine. Fluconazole may cause an increase in halofantrine plasma concentrations due to CYP3A4 inhibition. Concomitant use of these drugs may increase the risk of cardiotoxicity (QT interval prolongation, paroxysmal ventricular tachycardia of the “pirouette” type) and, consequently, sudden cardiac death. The combination of these drugs should be avoided. Concomitant use of fluconazole and the drugs listed below requires caution and dose adjustment.

Effects of Other Medications on Fluconazole.

Interaction studies have shown that oral administration of fluconazole concurrently with food, cimetidine, antacids, or subsequent total-body irradiation for bone marrow transplantation has no clinically significant effect on the absorption of fluconazole.

Rifampicin. Concomitant use of fluconazole and rifampicin resulted in a 25% decrease in AUC and a 20% reduction in the half-life of fluconazole. Therefore, for patients taking rifampicin, consideration should be given to increasing the dose of fluconazole.

Hydrochlorothiazide. In a pharmacokinetic interaction study, the concomitant repeated administration of hydrochlorothiazide to healthy volunteers receiving fluconazole increased the plasma concentration of fluconazole by 40%. These interaction parameters do not require changes to the fluconazole dosing regimen for patients who are concurrently receiving diuretics.

Effect of fluconazole on other drugs.

Fluconazole is a potent inhibitor of cytochrome P450 (CYP) 2C9 and a moderate inhibitor of CYP3A4. Fluconazole is an inhibitor of CYP2C19. In addition to the observed/documented interactions described below, concomitant use with fluconazole carries a risk of increased plasma concentrations of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4. Therefore, such drug combinations should be used with caution; patients should be closely monitored. The inhibitory effect of fluconazole on these enzymes persists for 4–5 days after administration due to its long half-life.

Alfentanil. During concomitant administration of alfentanil at a dose of 20 mcg/kg and fluconazole at a dose of 400 mg to healthy volunteers, a twofold increase in AUC10 was observed, possibly due to CYP3A4 inhibition. A dose adjustment of alfentanil may be necessary.

Amitriptyline, nortriptyline. Fluconazole potentiates the effects of amitriptyline and nortriptyline. It is recommended to measure concentrations of 5-nortryptiline and/or S-amitriptyline at the start of combination therapy and after 1 week. If necessary, the dose of amitriptyline/nortryptiline should be adjusted.

Amphotericin B. Concomitant administration of fluconazole and amphotericin B to infected mice with normal immunity and to infected mice with compromised immunity yielded the following results: a slight additive antifungal effect in systemic C. albicans infection, no interaction in intracranial Cryptococcus neoformans infection, and antagonism between the two drugs in systemic Aspergillus fumigatus infection. The clinical significance of the results obtained in these studies is unknown.

Anticoagulants. As with other azole antifungals, cases of bleeding (hematomas, epistaxis, gastrointestinal bleeding, hematuria, and melena) in combination with prolonged prothrombin time. When fluconazole and warfarin were used concomitantly, a twofold increase in prothrombin time was observed, presumably due to inhibition of warfarin metabolism via CYP2C9. Prothrombin time should be carefully monitored in patients who are concurrently taking coumarin anticoagulants or indandione. Adjustment of the anticoagulant dose may be necessary.

Short-acting benzodiazepines, such as midazolam and triazolam. Administration of fluconazole following oral administration of midazolam resulted in a significant increase in midazolam concentrations and an intensification of psychomotor effects. Concomitant administration of 200 mg of fluconazole and 7.5 mg of midazolam orally resulted in a 3.7-fold and 2.2-fold increase in AUC and half-life, respectively. Administration of 200 mg/day of fluconazole and 0.25 mg of triazolam orally resulted in a 4.4-fold and 2.3-fold increase in the AUC and half-life of triazolam, respectively. When fluconazole and triazolam were administered concomitantly, potentiation and prolongation of triazolam’s effects were observed. If a patient undergoing treatment with fluconazole is to be prescribed benzodiazepines concurrently, the dose of the benzodiazepines should be reduced, and the patient’s condition should be closely monitored.

Carbamazepine. Fluconazole inhibits the metabolism of carbamazepine and causes a 30% increase in serum carbamazepine levels. There is a risk of carbamazepine toxicity. It may be necessary to adjust the carbamazepine dose depending on its concentration and the drug’s effects. Calcium channel blockers. Some calcium antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by the CYP3A4 enzyme. Fluconazole may potentially increase the systemic exposure of calcium channel blockers. Close monitoring for the development of adverse reactions is recommended.

Celecoxib. When fluconazole (200 mg daily) and celecoxib (200 mg) were administered concomitantly, the Cmax and AUC of celecoxib increased by 68% and 134%, respectively. When celecoxib and fluconazole are used concomitantly, it may be necessary to reduce the celecoxib dose by half.

Cyclophosphamide. Concomitant use of cyclophosphamide and fluconazole leads to increased levels of bilirubin and creatinine in serum. These drugs may be used concomitantly, taking into account the risk of increased serum bilirubin and creatinine concentrations.

Fentanyl. One fatal case of fentanyl intoxication has been reported due to a possible interaction between fentanyl and fluconazole. Furthermore, a study involving healthy volunteers demonstrated that fluconazole significantly slowed the elimination of fentanyl. Increased fentanyl concentrations may lead to respiratory depression; therefore, the patient’s condition should be closely monitored. A dose adjustment of fentanyl may be necessary. HMG-CoA reductase inhibitors. Concomitant use of fluconazole and HMG-CoA reductase inhibitors metabolized by CYP3A4(atorvastatin and simvastatin), or HMG-CoA reductase inhibitors metabolized by CYP2C9 (fluvastatin), increases the risk of myopathy and rhabdomyolysis. If concomitant use of these drugs is necessary, the patient should be closely monitored for symptoms of myopathy and rhabdomyolysis, and creatine kinase levels should be monitored. If creatine kinase levels rise significantly, or if myopathy or rhabdomyolysis is diagnosed or suspected, HMG-CoA reductase inhibitors should be discontinued. Immunosuppressants (e.g., cyclosporine, everolimus, sirolimus, and tacrolimus).

Cyclosporine. Fluconazole significantly increases the concentration and AUC of cyclosporine. When fluconazole 200 mg/day was administered concomitantly with cyclosporine 2.7 mg/kg/day, the AUC of cyclosporine increased 1.8-fold. These drugs may be used concomitantly provided that the cyclosporine dose is reduced based on its concentration.

Everolimus. Although no in vitro or in vivo studies have been conducted, it is known that fluconazole may increase serum concentrations of everolimus through inhibition of CYP3A4.

Sirolimus: Fluconazole increases sirolimus plasma concentrations, presumably by inhibiting sirolimus metabolism by CYP3A4 and P-glycoprotein. These drugs may be used concomitantly provided that the sirolimus dose is adjusted based on drug concentrations and effects.

Tacrolimus. Fluconazole may increase tacrolimus serum concentrations up to 5-fold when administered orally due to inhibition of tacrolimus metabolism by CYP3A4 in the intestine. No significant changes in pharmacokinetics were observed with intravenous tacrolimus. Elevated tacrolimus levels are associated with nephrotoxicity. The dose of tacrolimus for oral administration should be reduced depending on the tacrolimus concentration.

Losartan. Fluconazole inhibits the metabolism of losartan to its active metabolite (E-3174), which accounts for most of the angiotensin II receptor antagonism during losartan administration. It is recommended to monitor blood pressure in patients on a regular basis.

Methadone. Fluconazole may increase serum methadone concentrations. When methadone and fluconazole are used concomitantly, adjustment of the methadone dose may be necessary.

Nonsteroidal anti-inflammatory drugs (NSAIDs). When administered concomitantly with fluconazole, the Cmax and AUC of flurbiprofen increased by 23% and 81%, respectively, compared with the corresponding values when flurbiprofen was administered alone. Similarly, when fluconazole was co-administered with racemic ibuprofen (400 mg), the Cmax and AUC of the pharmacologically active isomer S-(+)-ibuprofen increased by 15% and 82%, respectively, compared with the corresponding values when racemic ibuprofen was administered alone. Although no specific studies have been conducted, fluconazole may increase the systemic exposure of other NSAIDs metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). It is recommended to periodically monitor for adverse reactions and toxic effects associated with NSAIDs. Adjustment of the NSAID dose may be necessary.

Phenytoin. Fluconazole inhibits the metabolism of phenytoin in the liver. Concomitant multiple administration of 200 mg of fluconazole and 250 mg of phenytoin intravenously results in a 75% increase in phenytoin AUC24 and a 128% increase in Cmin. When these drugs are used concomitantly, serum phenytoin concentrations should be monitored to prevent the development of phenytoin toxicity.

Prednisone. There has been a reported case in which a patient who had undergone a liver transplant developed acute adrenal insufficiency while taking prednisone; this occurred after discontinuation of a three-month course of fluconazole therapy. Discontinuation of fluconazole likely caused an increase in CYP3A4 activity, leading to accelerated metabolism of prednisone. Patients who are taking fluconazole and prednisone concomitantly for an extended period should be closely monitored to prevent the development of adrenal insufficiency after discontinuation of fluconazole.

Rifabutin. Fluconazole increases rifabutin serum concentrations, leading to an increase in rifabutin AUC of up to 80%. Cases of uveitis have been reported with the concomitant use of fluconazole and rifabutin. When using this combination of medications, the symptoms of rifabutin toxicity should be monitored.

Saquinavir. Fluconazole increases the AUC and Cmax of saquinavir by approximately 50% and 55%, respectively, due to inhibition of saquinavir metabolism in the liver by the CYP3A4 enzyme and inhibition of P-glycoprotein. Interactions between fluconazole and saquinavir/ritonavir have not been studied; therefore, these effects may be more pronounced. A dose adjustment of saquinavir may be necessary.

Sulfonylurea derivatives. When administered concomitantly, fluconazole prolongs the half-life of oral sulfonylurea derivatives (chlorpropamide, glibenclamide, glipizide, and tolbutamide) when administered to healthy volunteers. Frequent monitoring of blood glucose levels is recommended, and the dose of sulfonylurea derivatives should be reduced accordingly when used concomitantly with fluconazole.

Theophylline. In a drug interaction study, administration of 200 mg of fluconazole daily for 14 days resulted in an 18% decrease in the mean plasma clearance of theophylline. Patients receiving high doses of theophylline or who are at increased risk of theophylline toxicity for other reasons should be monitored for signs of theophylline toxicity. Therapy should be adjusted if signs of toxicity appear.

Periwinkle alkaloids. Although no specific studies have been conducted, fluconazole, likely due to CYP3A4 inhibition, may cause an increase in plasma concentrations of periwinkle alkaloids (e.g., vincristine and vinblastine), leading to the development of neurotoxic effects.

Vitamin A. It has been reported that a patient who was taking both transretinoic acid (the acid form of vitamin A) and fluconazole experienced central nervous system (CNS) adverse reactions in the form of pseudotumor cerebri; this effect resolved after discontinuation of fluconazole. These medications may be used concomitantly, but the risk of CNS adverse reactions should be kept in mind.

Voriconazole (an inhibitor of CYP2C9, CYP2C19, and CYP3A4).Concomitant administration of oral voriconazole (400 mg every 12 hours for 1 day, followed by 200 mg every 12 hours for 2.5 days) and oral fluconazole (400 mg on the first day, followed by 200 mg every 24 hours for 4 days) in 8 healthy male volunteers resulted in an increase in the Cmax and AUC of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. It is unknown whether reducing the dose and/or frequency of voriconazole or fluconazole administration eliminates this effect. When voriconazole is administered following fluconazole, patients should be monitored for the development of adverse effects associated with voriconazole.

Zidovudine. Fluconazole increases the Cmax and AUC of zidovudine by 84% and 74%, respectively, due to a reduction in zidovudine clearance of approximately 45% following oral administration. The half-life of zidovudine was also prolonged by approximately 128% following co-administration of fluconazole and zidovudine. Patients receiving this combination of medications should be monitored for the development of adverse reactions associated with zidovudine use. Consideration should be given to reducing the zidovudine dose.

Azithromycin. Studies evaluated the effect of azithromycin and fluconazole on each other’s pharmacokinetics following simultaneous single oral administration at doses of 1,200 mg and 800 mg, respectively. No significant pharmacokinetic interactions were observed.

Oral contraceptives. When fluconazole was administered at a dose of 50 mg, there was no effect on hormone levels, whereas administration of 200 mg of fluconazole daily resulted in a 40% increase in the AUC of ethinyl estradiol and a 24% increase in the AUC of levonorgestrel. This suggests that repeated administration of fluconazole at these doses is unlikely to affect the efficacy of combined oral contraceptives.

Ivacaftor. Concomitant use with ivacaftor, an activator of the cystic fibrosis transmembrane conductance regulator, increases the exposure to ivacaftor 3-fold, and that of hydroxymethyl-ivacaftor (M1) by 1.9 times. For patients who are also taking moderate CYP3A inhibitors, such as fluconazole and erythromycin, a reduction in the ivacaftor dose to 150 mg once daily is recommended.

Special Considerations for Use

Dermatophytosis. According to the results of a study of fluconazole for the treatment of dermatophytosis in children, fluconazole is no more effective than griseofulvin, and the overall efficacy rate is less than 20%. Therefore, fluconazole should not be used to treat dermatophytosis.

Cryptococcosis. There is insufficient evidence of fluconazole’s efficacy for treating cryptococcosis in other sites (e.g., pulmonary cryptococcosis and cutaneous cryptococcosis); therefore, there are no dosage recommendations for treating these conditions.

Deep endemic mycoses. There is insufficient evidence of the efficacy of fluconazole for the treatment of other forms of endemic mycoses, such as paracoccidioidomycosis, histoplasmosis, and cutaneous-lymphatic sporotrichosis; therefore, there are no dosage recommendations for the treatment of such conditions.

Renal system. The drug should be used with caution in patients with impaired renal function (see the “Dosage and Administration” section). Adrenal insufficiency. Ketoconazole is known to cause adrenal insufficiency, and this may also apply to fluconazole, although it is rarely observed. Adrenal insufficiency associated with concomitant therapy is described in the section “Effects of Fluconazole on Other Medications.”

Hepatobiliary system. The drug should be used with caution in patients with impaired liver function. The use of fluconazole has been associated with rare cases of severe hepatotoxicity, including fatal outcomes, primarily in patients with severe underlying medical conditions. In cases where the development of hepatotoxicity was associated with the use of fluconazole, no clear correlation was observed with the total daily dose of the drug, duration of therapy, gender, or age of the patient. Hepatotoxicity caused by fluconazole is usually reversible, and its symptoms resolve after discontinuation of therapy. Patients who exhibit abnormal liver function test results while taking fluconazole should be closely monitored for the development of more severe liver damage. Patients should be informed of symptoms that may indicate serious liver damage (severe asthenia, anorexia, persistent nausea, vomiting, and jaundice). In such cases, fluconazole should be discontinued immediately, and a physician should be consulted.

Cardiovascular system. Some azoles, including fluconazole, are associated with QT interval prolongation on the electrocardiogram. Very rare cases of QT interval prolongation and paroxysmal ventricular tachycardia of the “pirouette” type have been reported with the use of this medication. These reports involved patients with severe illnesses and a combination of multiple risk factors, such as structural heart disease, electrolyte imbalances, and concomitant use of other medications that affect the QT interval. Fluconazole should be used with caution in patients at risk of developing arrhythmias. Concomitant use with drugs that prolong the QTc interval and are metabolized by the CYP3A4 enzyme of cytochrome P450 is contraindicated.

Halofantrine. Halofantrine is a substrate of the CYP3A4 enzyme and prolongs the QTc interval when used at recommended therapeutic doses. Concomitant use of halofantrine and fluconazole is not recommended. Dermatological reactions. Rare cases of exfoliative skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported with fluconazole use. Patients with AIDS are more prone to developing severe skin reactions when taking many medications. If a patient with a superficial fungal infection develops a rash that may be related to fluconazole use, further administration of the drug should be discontinued. If a patient with an invasive/systemic fungal infection develops a skin rash, the patient’s condition should be closely monitored; if bullous rashes or erythema multiforme develop, fluconazole should be discontinued.

Hypersensitivity. In rare cases, anaphylactic reactions have been reported.

Cytochrome P450. Fluconazole is a potent inhibitor of the CYP2C9 enzyme and a moderate inhibitor of the CYP3A4 enzyme. Fluconazole is also an inhibitor of the CYP2C19 enzyme. Patients receiving concomitant treatment with fluconazole and drugs with a narrow therapeutic index that are metabolized by CYP2C9, CYP2C19, and CYP3A4 should be monitored closely.

Terfenadine. Patients should be closely monitored when terfenadine is used concomitantly with fluconazole at a dose of less than 400 mg per day.

Inactive ingredients.

This medication contains lactose.

Patients with rare hereditary disorders, such as galactose intolerance, Lapp lactase deficiency, and glucose-galactose malabsorption, should not take this medication.

Use During Pregnancy and Lactation

Numerous congenital anomalies have been reported in newborns (including brachycephaly, auricular dysplasia, excessive enlargement of the anterior fontanelle, hip deformity, and humeroradial synostosis) whose mothers received high doses of fluconazole (400–800 mg/day) for at least three or more months to treat coccidioidomycosis. A causal relationship between fluconazole use and these cases has not been established.

Animal studies have demonstrated reproductive toxicity.

Data obtained from single or repeated administration of fluconazole at usual doses (<200 mg/day) to several hundred pregnant women during the first trimester of pregnancy did not show an increased risk of adverse fetal outcomes.

Usual doses of fluconazole and short-term courses of fluconazole therapy should not be used during pregnancy unless absolutely necessary.

High doses of fluconazole and/or prolonged courses of fluconazole treatment should not be used during pregnancy, except for the treatment of life-threatening infections.

Fluconazole passes into breast milk at concentrations lower than those in blood plasma.

Breastfeeding may be continued after a single administration of a standard dose of fluconazole of 200 mg or less. Breastfeeding is not recommended with repeated administration of fluconazole or with high doses of fluconazole.

Effect on the ability to drive or operate machinery

No studies have been conducted on the drug’s effect on the ability to drive or operate machinery.

Patients should be informed of the possibility of dizziness or seizures while taking this medication. If such symptoms occur, driving or operating machinery is not recommended.

Dosage and Administration

Swallow the capsules whole. The drug may be taken with or without food.

Adults.

The drug is administered orally at a single dose of 150 mg.

Elderly patients.

In the absence of signs of renal impairment, the usual adult dose is used to treat this patient population.

Renal impairment.

Fluconazole is excreted primarily in the urine in its unchanged form. For a single dose, no dose adjustment is required for this patient population.

Hepatic impairment.

Fluconazole should be used with caution in patients with hepatic impairment, as there is insufficient information regarding the use of fluconazole in this patient population.

Children

The efficacy and safety of the drug for the treatment of genital candidiasis in children have not been established, despite extensive data on its use in children. If there is an urgent need to administer the drug to adolescents (ages 12 to 17), the usual adult doses should be used.

Overdose

Cases of fluconazole overdose have been reported; hallucinations and paranoid behavior have also been reported.

In case of overdose, symptomatic supportive therapy should be provided, and gastric lavage should be performed if necessary.

Fluconazole is largely excreted in the urine; forced diuresis may accelerate the drug’s elimination. A 3-hour hemodialysis session reduces plasma fluconazole levels by approximately 50%.

Side Effects

The following adverse reactions were reported most frequently (> 1/10): headache, abdominal pain, diarrhea, nausea, vomiting, rash, and elevated levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in the blood. The following classification is used to assess the frequency of adverse reactions: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1,000, < 1/100), rare (≥ 1/10,000, < 1/1,000), very rare (< 1/10,000), frequency unknown (cannot be estimated from the available data).

Blood disorders: uncommon—anemia; rare—agranulocytosis, leukopenia, neutropenia, thrombocytopenia.

Immune system disorders: rare – anaphylaxis.

Metabolic disorders: uncommon—decreased appetite; rare—hypertriglyceridemia, hypercholesterolemia, hypokalemia.

Psychiatric disorders: uncommon—insomnia, drowsiness.

Nervous system disorders: common—headache; uncommon—seizures, dizziness, paresthesia, taste disturbances; rare—tremor.

Ear disorders: uncommon – vertigo.

Cardiac: rarely—paroxysmal ventricular tachycardia of the “pirouette” type, QT interval prolongation.

Gastrointestinal system: common – abdominal pain, diarrhea, nausea, vomiting; uncommon – constipation, dyspepsia, flatulence, dry mouth.

Hepatobiliary system: common – elevated ALT, AST, and LFT levels; uncommon – cholestasis, jaundice, elevated bilirubin levels; Rarely—liver failure, hepatocellular necrosis, hepatitis, hepatocellular damage.

Skin and subcutaneous tissue disorders: common—rash; uncommon—pruritus, drug-induced dermatitis (including fixed drug eruption), urticaria, increased sweating; Rarely—toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, angioedema, facial swelling, alopecia.

Musculoskeletal system: uncommon – myalgia.

General disorders: uncommon—increased fatigue, malaise, asthenia, fever.

Children.

Frequency and nature of adverse reactions and abnormal laboratory test results in clinical trials involving children compared to those in adults.

Reporting of Suspected Adverse Reactions.

Reporting suspected adverse reactions after the drug’s approval is of great importance. This allows for continuous monitoring of the benefit-risk profile associated with the use of this drug. Healthcare professionals are asked to report any suspected adverse reactions in accordance with local regulations.

Shelf life

2 years.

Storage Conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Dosage Form

1 capsule per blister pack; 1, 2, 3, or 4 blister packs per box.

Dispensing Category

150 mg No. 1 – available without a prescription.

150 mg No. 2; No. 3; No. 4 – by prescription.